AU2019360941B2 - TYK2 inhibitors and uses thereof - Google Patents

TYK2 inhibitors and uses thereof Download PDF

Info

Publication number
AU2019360941B2
AU2019360941B2 AU2019360941A AU2019360941A AU2019360941B2 AU 2019360941 B2 AU2019360941 B2 AU 2019360941B2 AU 2019360941 A AU2019360941 A AU 2019360941A AU 2019360941 A AU2019360941 A AU 2019360941A AU 2019360941 B2 AU2019360941 B2 AU 2019360941B2
Authority
AU
Australia
Prior art keywords
nitrogen
sulfur
oxygen
independently selected
heteroatoms independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019360941A
Other languages
English (en)
Other versions
AU2019360941A1 (en
Inventor
Jeremy Robert Greenwood
Craig E. Masse
Sayan Mondal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2019360941A1 publication Critical patent/AU2019360941A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: NIMBUS LAKSHMI, INC.
Application granted granted Critical
Publication of AU2019360941B2 publication Critical patent/AU2019360941B2/en
Priority to AU2025203926A priority Critical patent/AU2025203926A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019360941A 2018-10-15 2019-10-15 TYK2 inhibitors and uses thereof Active AU2019360941B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203926A AU2025203926A1 (en) 2018-10-15 2025-05-27 TYK2 inhibitors and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862745642P 2018-10-15 2018-10-15
US62/745,642 2018-10-15
US201962795869P 2019-01-23 2019-01-23
US62/795,869 2019-01-23
US201962820509P 2019-03-19 2019-03-19
US62/820,509 2019-03-19
PCT/US2019/056230 WO2020081508A1 (en) 2018-10-15 2019-10-15 Tyk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203926A Division AU2025203926A1 (en) 2018-10-15 2025-05-27 TYK2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2019360941A1 AU2019360941A1 (en) 2021-04-29
AU2019360941B2 true AU2019360941B2 (en) 2025-02-27

Family

ID=70284120

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019360941A Active AU2019360941B2 (en) 2018-10-15 2019-10-15 TYK2 inhibitors and uses thereof
AU2025203926A Pending AU2025203926A1 (en) 2018-10-15 2025-05-27 TYK2 inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203926A Pending AU2025203926A1 (en) 2018-10-15 2025-05-27 TYK2 inhibitors and uses thereof

Country Status (8)

Country Link
US (2) US11414431B2 (https=)
EP (1) EP3866789A4 (https=)
JP (2) JP7619951B2 (https=)
CN (1) CN113271940A (https=)
AU (2) AU2019360941B2 (https=)
CA (1) CA3115088A1 (https=)
IL (2) IL282090B2 (https=)
WO (1) WO2020081508A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
JP2022519696A (ja) * 2019-02-07 2022-03-24 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
CA3134814A1 (en) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
CN115052660B (zh) 2020-02-12 2024-01-09 伊莱利利公司 取代的7-(甲氨基)吡唑并[1,5-a]嘧啶-3-甲酰胺衍生物
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
WO2022156657A1 (en) * 2021-01-19 2022-07-28 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions
CA3213816A1 (en) 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
US20250213572A1 (en) * 2022-03-25 2025-07-03 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
AR128868A1 (es) * 2022-03-25 2024-06-19 Nimbus Lakshmi Inc Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
WO2026033474A1 (en) 2024-08-08 2026-02-12 Takeda Pharmaceutical Company Limited Deuterated compounds and uses thereof
WO2026037386A1 (zh) * 2024-08-15 2026-02-19 成都肯迪特生物医药科技有限公司 一种具有tyk2抑制作用的化合物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123738A1 (en) * 2004-06-21 2005-12-29 F.Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
US20060128725A1 (en) * 2002-09-04 2006-06-15 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070072882A1 (en) * 2002-09-04 2007-03-29 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070072881A1 (en) * 2002-09-04 2007-03-29 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
WO2011006074A1 (en) * 2009-07-09 2011-01-13 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CN101107251A (zh) * 2005-01-19 2008-01-16 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶-ⅳ抑制剂的双环嘧啶类
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
JP5052518B2 (ja) * 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
NZ598220A (en) * 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
EP2525659B1 (en) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
EP3366688B1 (en) * 2010-12-08 2022-02-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
KR101923367B1 (ko) * 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
CN104302649B (zh) * 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015073267A1 (en) * 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4406616A3 (en) * 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
CN107076795B (zh) 2014-11-21 2020-05-05 三菱电机株式会社 局部放电位置标定装置
CA2971024C (en) * 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
JP6800158B2 (ja) * 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
US10155765B2 (en) * 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
TW202515876A (zh) 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN113348021B (zh) 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128725A1 (en) * 2002-09-04 2006-06-15 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070072882A1 (en) * 2002-09-04 2007-03-29 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070072881A1 (en) * 2002-09-04 2007-03-29 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2005123738A1 (en) * 2004-06-21 2005-12-29 F.Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
WO2011006074A1 (en) * 2009-07-09 2011-01-13 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Also Published As

Publication number Publication date
IL324623A (en) 2026-01-01
CA3115088A1 (en) 2020-04-23
CN113271940A (zh) 2021-08-17
US11414431B2 (en) 2022-08-16
IL282090B2 (en) 2026-04-01
EP3866789A1 (en) 2021-08-25
WO2020081508A1 (en) 2020-04-23
JP7619951B2 (ja) 2025-01-22
JP2022502515A (ja) 2022-01-11
IL282090B1 (en) 2025-12-01
AU2019360941A1 (en) 2021-04-29
JP2025061147A (ja) 2025-04-10
US20230110996A1 (en) 2023-04-13
AU2025203926A1 (en) 2025-06-19
EP3866789A4 (en) 2022-07-06
IL282090A (en) 2021-05-31
US20200131201A1 (en) 2020-04-30
US12221453B2 (en) 2025-02-11

Similar Documents

Publication Publication Date Title
AU2019360941B2 (en) TYK2 inhibitors and uses thereof
AU2018306444B2 (en) TYK2 inhibitors and uses thereof
AU2017345736B2 (en) TYK2 inhibitors and uses thereof
JP7508584B2 (ja) ＰＩ３Ｋα阻害剤およびそれらの使用
CA3150108A1 (en) Hpk1 antagonists and uses thereof
CA3016182C (en) Substituted indole mcl-1 inhibitors
AU2019318543B2 (en) Transglutaminase 2 (TG2) inhibitors
AU2017342464B2 (en) TYK2 inhibitors and uses thereof
CA2972797C (en) Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
EP3262049B1 (en) Tyk2 inhibitors and uses thereof
CA3120866A1 (en) Tyk2 inhibitors and uses thereof
AU2005294575A1 (en) Lactam compounds useful as protein kinase inhibitors
JP2025519029A (ja) ＰＩ３Ｋα阻害剤及びその使用方法
CA3266321A1 (en) HETEROBORCTIONAL COMPOUNDS AND METHODS OF DISEASE TREATMENT
CA3109195C (en) Transglutaminase 2 (tg2) inhibitors
EA049284B1 (ru) ИНГИБИТОРЫ PI3Kα И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2025097090A1 (en) Substituted (piperidin-4-yl)-1,5-naphthyridine and (piperidin-4-yl)quinoline derivatives and uses thereof
WO2026096385A1 (en) Heteroaryl compounds useful as tyk2 inhibitors
EA052562B1 (ru) ИНГИБИТОРЫ PI3Kα И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR122025014062A2 (pt) Inibidores de tyk2, composição farmacêutica, usos dos mesmos e método de inibição de tyk2 em uma amostra biológica
HK40009936B (en) Tyk2 inhibitors and uses thereof
HK40009936A (en) Tyk2 inhibitors and uses thereof
HK1248690B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): NIMBUS LAKSHMI, INC.

FGA Letters patent sealed or granted (standard patent)